SG11201907211TA - Anti-pd-l1 antibody treatment of bladder cancer - Google Patents
Anti-pd-l1 antibody treatment of bladder cancerInfo
- Publication number
- SG11201907211TA SG11201907211TA SG11201907211TA SG11201907211TA SG11201907211TA SG 11201907211T A SG11201907211T A SG 11201907211TA SG 11201907211T A SG11201907211T A SG 11201907211TA SG 11201907211T A SG11201907211T A SG 11201907211TA SG 11201907211T A SG11201907211T A SG 11201907211TA
- Authority
- SG
- Singapore
- Prior art keywords
- medimmune
- llc
- gaithersburg
- way
- bladder cancer
- Prior art date
Links
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 title abstract 9
- 206010005003 Bladder cancer Diseases 0.000 title abstract 8
- 201000005112 urinary bladder cancer Diseases 0.000 title abstract 8
- 238000011282 treatment Methods 0.000 title abstract 5
- 238000000034 method Methods 0.000 abstract 3
- 238000002560 therapeutic procedure Methods 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 229950009791 durvalumab Drugs 0.000 abstract 1
- 238000009093 first-line therapy Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229910052697 platinum Inorganic materials 0.000 abstract 1
- 206010044412 transitional cell carcinoma Diseases 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
- 229950007217 tremelimumab Drugs 0.000 abstract 1
- 208000023747 urothelial carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762459700P | 2017-02-16 | 2017-02-16 | |
| PCT/US2018/018513 WO2018152415A1 (en) | 2017-02-16 | 2018-02-16 | Anti-pd-l1 antibody treatment of bladder cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907211TA true SG11201907211TA (en) | 2019-09-27 |
Family
ID=63169615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907211TA SG11201907211TA (en) | 2017-02-16 | 2018-02-16 | Anti-pd-l1 antibody treatment of bladder cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20190359715A1 (enExample) |
| EP (1) | EP3582805A4 (enExample) |
| JP (2) | JP2020507596A (enExample) |
| KR (3) | KR20230145547A (enExample) |
| CN (2) | CN118001389A (enExample) |
| AU (2) | AU2018221822A1 (enExample) |
| CA (1) | CA3052652A1 (enExample) |
| EA (1) | EA201991870A1 (enExample) |
| IL (3) | IL320916A (enExample) |
| MA (1) | MA47509A (enExample) |
| SG (1) | SG11201907211TA (enExample) |
| WO (1) | WO2018152415A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122023025321A2 (pt) * | 2014-05-13 | 2024-02-20 | Medimmune Limited | Uso de anticorpos anti-b7-h1 e anti-ctla-4 |
| KR20230145547A (ko) * | 2017-02-16 | 2023-10-17 | 메디뮨 엘엘씨 | 방광암의 항-pd-l1 항체 치료 |
| KR20200016899A (ko) | 2017-06-01 | 2020-02-17 | 싸이톰스 테라퓨틱스, 인크. | 활성화가능 항-pdl1 항체, 및 이의 이용 방법 |
| WO2021234150A1 (en) * | 2020-05-21 | 2021-11-25 | Astrazeneca Ab | Tumor mutational burden associated with sensitivity to immunotherapy in locally advanced or metastatic urothelial carcinoma |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7947261B2 (en) * | 2003-05-23 | 2011-05-24 | Nektar Therapeutics | Conjugates formed from polymer derivatives having particular atom arrangements |
| BR122023025321A2 (pt) * | 2014-05-13 | 2024-02-20 | Medimmune Limited | Uso de anticorpos anti-b7-h1 e anti-ctla-4 |
| BR112017018234A2 (pt) * | 2015-02-26 | 2018-04-17 | Merck Patent Gmbh | inibidores de pd-1 / pd-l1 para o tratamento de câncer |
| PL3303632T5 (pl) * | 2015-05-29 | 2023-07-03 | F. Hoffmann-La Roche Ag | Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze |
| EP3387155A4 (en) * | 2015-12-10 | 2019-06-12 | Definiens AG | METHOD FOR THE TREATMENT AND SELECTION OF PATIENTS THAT APPLY TO IMMUNE-ACTED CANCER THERAPY |
| EP3448428A4 (en) * | 2016-04-25 | 2019-11-27 | Medimmune, LLC | COMPOSITIONS WITH CO FORMULATION OF ANTI-PD-L1 AND ANTI-CTLA-4 ANTIBODIES |
| KR20230145547A (ko) * | 2017-02-16 | 2023-10-17 | 메디뮨 엘엘씨 | 방광암의 항-pd-l1 항체 치료 |
-
2018
- 2018-02-16 KR KR1020237034594A patent/KR20230145547A/ko not_active Ceased
- 2018-02-16 SG SG11201907211TA patent/SG11201907211TA/en unknown
- 2018-02-16 MA MA047509A patent/MA47509A/fr unknown
- 2018-02-16 EA EA201991870A patent/EA201991870A1/ru unknown
- 2018-02-16 AU AU2018221822A patent/AU2018221822A1/en not_active Abandoned
- 2018-02-16 CA CA3052652A patent/CA3052652A1/en active Pending
- 2018-02-16 KR KR1020257004753A patent/KR20250025517A/ko active Pending
- 2018-02-16 WO PCT/US2018/018513 patent/WO2018152415A1/en not_active Ceased
- 2018-02-16 IL IL320916A patent/IL320916A/en unknown
- 2018-02-16 US US16/486,222 patent/US20190359715A1/en not_active Abandoned
- 2018-02-16 JP JP2019543851A patent/JP2020507596A/ja active Pending
- 2018-02-16 IL IL302777A patent/IL302777A/en unknown
- 2018-02-16 KR KR1020197026803A patent/KR20190117014A/ko not_active Ceased
- 2018-02-16 CN CN202410133870.XA patent/CN118001389A/zh active Pending
- 2018-02-16 CN CN201880011428.2A patent/CN110290803A/zh active Pending
- 2018-02-16 EP EP18753778.2A patent/EP3582805A4/en active Pending
-
2019
- 2019-08-04 IL IL268460A patent/IL268460A/en unknown
-
2022
- 2022-04-14 US US17/720,903 patent/US20220332828A1/en active Pending
-
2023
- 2023-12-22 JP JP2023216425A patent/JP2024038034A/ja active Pending
-
2025
- 2025-02-21 AU AU2025201227A patent/AU2025201227A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL268460A (en) | 2019-09-26 |
| IL320916A (en) | 2025-07-01 |
| EP3582805A1 (en) | 2019-12-25 |
| US20220332828A1 (en) | 2022-10-20 |
| CA3052652A1 (en) | 2018-08-23 |
| JP2020507596A (ja) | 2020-03-12 |
| EP3582805A4 (en) | 2021-03-10 |
| EA201991870A1 (ru) | 2020-02-12 |
| KR20230145547A (ko) | 2023-10-17 |
| CN110290803A (zh) | 2019-09-27 |
| KR20190117014A (ko) | 2019-10-15 |
| IL302777A (en) | 2023-07-01 |
| US20190359715A1 (en) | 2019-11-28 |
| JP2024038034A (ja) | 2024-03-19 |
| AU2025201227A1 (en) | 2025-03-13 |
| MA47509A (fr) | 2019-12-25 |
| CN118001389A (zh) | 2024-05-10 |
| KR20250025517A (ko) | 2025-02-21 |
| WO2018152415A1 (en) | 2018-08-23 |
| AU2018221822A1 (en) | 2019-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201900885VA (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| SG11201804839WA (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
| SG11201809089QA (en) | Bispecific binding proteins and uses thereof | |
| SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
| SG11201907211TA (en) | Anti-pd-l1 antibody treatment of bladder cancer | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201909572QA (en) | Methods for the treatment of subjects having a hepatitis b virus (hbv) infection | |
| SG11201900677SA (en) | Combination therapies of chimeric antigen receptors adn pd-1 inhibitors | |
| SG11201808242UA (en) | Methods for inhibiting angiogenesis in a subject in need thereof | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201900344YA (en) | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor | |
| SG11201810883TA (en) | Combination therapy | |
| SG11201806340YA (en) | Zika virus vaccine | |
| SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| SG11201806251WA (en) | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody | |
| SG11201901961SA (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x | |
| SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
| SG11201811292RA (en) | Compositions and methods for the depletion of cells | |
| SG11201809764XA (en) | Humanized anti-il-1r3 antibodies | |
| SG11201808314QA (en) | Compositions and methods for the treatment of wounds, disorders, and diseases of the skin | |
| SG11201900745VA (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors |